🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06984731
Recruiting Observational

The Safety and Efficacy of Radiofrequency Ablation After Left Atrial Appendage Occlusion.

NCT06984731 · tracked via the Priya Life Science China tracker
Sponsor
Affiliated Hospital of Nantong University
Phase
Observational
Started
2025-04-21
Last updated
2025-05-22

Condition(s) studied

Cardiovascular DiseasesArrhythmia

Investigational drug(s) / intervention(s)

left atrial appendage closureradiofrequency ablation

left atrial appendage closure: Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX

radiofrequency ablation: Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX

Study summary

Objective: To evaluate the safety and efficacy of transcatheter atrial fibrillation ablation 1 month after WATCHMAN FLX left atrial appendage closure in patients with nonvalvular atrial fibrillation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. ≥18 years of age, diagnosed with nonvalvular atrial fibrillation; 2. Meet the indications for receiving WATCHMAN FLX left atrial appendicular closure and transcatheter atrial fibrillation ablation; 3. Preoperative imaging evaluation showed that the anatomical structure of the left atrial appendage was suitable for implantation with the WATCHMAN FLX device; 4. The patient agrees to participate in the study and signs the informed consent. Exclusion Criteria: 1. valvular heart disease or other structural heart disease that causes atrial fibrillation; 2. left auricular thrombus or acute thrombotic event was found before surgery; 3. Patients with severe bleeding tendency or recent major bleeding events (such as massive gastrointestinal bleeding, cerebral hemorrhage, etc.); 4. Patients who are unable to complete postoperative follow-up (such as life expectancy of less than 1 year or poor compliance); 5. Other serious diseases (such as liver and kidney failure, active infection, etc.) were found in preoperative examination; 6. Pregnant or lactating women.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Affiliated hospital of Nantong University Nantong Jiangsu Recruiting

More Affiliated Hospital of Nantong University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06984731 on ClinicalTrials.gov ↗ ← All trials in China